These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19404206)

  • 21. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin.
    Kavak A; Akcan Y; Korkmaz U
    Dermatology; 2005; 211(2):171-2. PubMed ID: 16088172
    [No Abstract]   [Full Text] [Related]  

  • 22. Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin.
    Watanabe T; Hirono H; Hasegawa K; Soga K; Shibasaki K
    J Gastroenterol Hepatol; 2011 Dec; 26(12):1709-16. PubMed ID: 22097938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevention of adverse effects in ribavirin and interferon combination therapy].
    Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):523-7. PubMed ID: 15359855
    [No Abstract]   [Full Text] [Related]  

  • 24. [Evaluation of tolerance and efficacy of the treatment of chronic viral hepatitis C in homozygous sickle cell patients].
    El Agheb MO; Grange JD
    Pan Afr Med J; 2015; 20():99. PubMed ID: 26213600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic behaviour for a HCV+ patient].
    Buffet C
    Presse Med; 2004 Apr; 33(7):497-8. PubMed ID: 15105775
    [No Abstract]   [Full Text] [Related]  

  • 26. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H; Gardner A; Usher K
    J Clin Nurs; 2011 May; 20(9-10):1215-24. PubMed ID: 21371144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: a comparative study.
    Soliman AT; elZalabany M; Amer M; Ansari BM
    J Trop Pediatr; 1999 Feb; 45(1):23-30. PubMed ID: 10191589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualization of antiviral treatment regimens for chronic hepatitis C.
    Paulon E; Naoumov NV
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
    Suzuki M; Inage E; Minowa K; Saito N; Naritaka N; Tsubahara M; Ohtsuka Y; Tokita A; Shimizu T
    Pediatr Int; 2012 Aug; 54(4):528-31. PubMed ID: 22375604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy.
    Chang SC; Ko WS; Wu SS; Peng CY; Yang SS
    J Formos Med Assoc; 2008 Jun; 107(6):454-62. PubMed ID: 18583216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Peripheral facial paralysis during interferon treatment in hepatitis C: recovery without antiviral therapy withdrawal].
    de Artaza T; Sánchez JJ; González C; Pérez-Grueso MJ; Repiso A; Gómez R; Potenciano JL
    Gastroenterol Hepatol; 2004; 27(7):434-5. PubMed ID: 15461949
    [No Abstract]   [Full Text] [Related]  

  • 32. [Type 2 diabetes mellitus with histological finding of nonalcoholic steatohepatitis following combination therapy with interferon and ribavirin for chronic hepatitis C].
    Yagi N; Uchikoga O; Nishumi T; Shibutani Y; Fukunaga K; Yagi N; Morita M; Tani S; Murao S
    Nihon Shokakibyo Gakkai Zasshi; 2005 Aug; 102(8):1045-50. PubMed ID: 16124712
    [No Abstract]   [Full Text] [Related]  

  • 33. Weight loss with interferon and ribavirin therapy in chronic hepatitis C patients.
    Sajjad SF; Ahmed Wu; Arif A; Alam SE; Waquar J
    J Pak Med Assoc; 2012 Nov; 62(11):1229-32. PubMed ID: 23866417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
    Chang CH; Chen KY; Lai MY; Chan KA
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1623-32. PubMed ID: 12197841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea.
    Ahn YH; Park H; Lee MJ; Kim DH; Cho SB; Cho E; Jun CH; Choi SK
    Gut Liver; 2019 Sep; 13(5):549-556. PubMed ID: 30970433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focus. The impact of ribavirin treatment on spermatogenesis inpatients with chronic hepatitis C.
    Shouval D
    J Hepatol; 2010 Jun; 52(6):781-2. PubMed ID: 20392511
    [No Abstract]   [Full Text] [Related]  

  • 37. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus.
    Paraná R; Cruz M; Lyra L; Cruz T
    J Viral Hepat; 2000 Sep; 7(5):393-5. PubMed ID: 10971829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
    Bizollon T; Trepo C
    J Hepatol; 2002 Aug; 37(2):274-6. PubMed ID: 12127435
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of hepatitis C antiviral therapy in moderate and severe chronic kidney disease.
    Ramachandran J; Mahajan R; Basu G; Alagammai PL; Sivakumar J; Goel A; Abraham P; Tamilarasi V
    Indian J Gastroenterol; 2014 Sep; 33(5):471-5. PubMed ID: 25015745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent progress in the treatment of interferon-resistant hepatitis C].
    Kumada M
    Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1759-62. PubMed ID: 10581760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.